Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

Investment analysts at StockNews.com initiated coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research note issued on Thursday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

A number of other analysts also recently weighed in on TENX. Leerink Partners set a $20.00 target price on Tenax Therapeutics in a research report on Monday. William Blair reiterated an “outperform” rating on shares of Tenax Therapeutics in a research report on Monday. One investment analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tenax Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Tenax Therapeutics Stock Up 3.4 %

Shares of NASDAQ TENX opened at $6.40 on Thursday. The stock’s fifty day moving average price is $6.44 and its two-hundred day moving average price is $5.21. Tenax Therapeutics has a one year low of $2.77 and a one year high of $7.89.

Institutional Trading of Tenax Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Two Sigma Investments LP bought a new stake in shares of Tenax Therapeutics during the 4th quarter worth $84,000. Millennium Management LLC bought a new stake in shares of Tenax Therapeutics during the 4th quarter worth $166,000. Janus Henderson Group PLC bought a new stake in shares of Tenax Therapeutics during the 4th quarter worth $1,026,000. Geode Capital Management LLC lifted its position in shares of Tenax Therapeutics by 32.4% during the 4th quarter. Geode Capital Management LLC now owns 24,354 shares of the specialty pharmaceutical company’s stock worth $151,000 after buying an additional 5,964 shares during the last quarter. Finally, Sphera Funds Management LTD. bought a new stake in shares of Tenax Therapeutics during the 3rd quarter worth $101,000. 1.67% of the stock is currently owned by institutional investors.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.